There was no evidence for treatment-related normalization in SS-A, SS-B autoantibody titers, or β2-microglobulin, complement components 3 (C3) or C4, or hemolytic complement (CH50) levels (Supplemental Table 2). Here, C4A is linked to synovial sarcoma.